English (UK)
中文版Mr. Kenneth Xu
Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn
Genova Inc
Vice President & Corporate SecretaryMr. Paul Xu
The North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based, business service provider representing the City of Shenzhen, China´s first Special Economic Zone. Directly sponsored by the Shenzhen Municipal Government and Invest Shenzhen, NAROS offers guidance and consultation to North American companies wishing to enter the Chinese market by means of direct investment within in the City of Shenzhen, as well as to Shenzhen-based companies looking to enter the North American market.
North American Rep. Office of Shenzhen
Business Development SpecialistDr. Chuanbo Xu
Liquid biopsy blood test for early detection of cancers
Freenome, Inc.
Senior Director, Clinical DevelopmentMrs. Shirley Xu
Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Yonghua Capital
Executive DirectorMr. Evan Xu
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Genetron Health
Chief Financial OfficerDr. Zhenyan Yan
Founded in 2002, GenScript is committed to making humans and environment healthier through innovation. With its over 3,000 employees globally and R&D centers in the U.S., China and Europe, GenScript has become a global leader in providing research, biologics development services, synthetic biology products as well as a world class leader in cell therapy to help patients conquer serious diseases
Responsive Web Design powered by 